Debiopharm, SunRock sign agreement for cancer ADCs
22 Sep 2023
License out/inADC
Preview
Source: Pharmaceutical Technology
The partnership will advance antibody drug conjugates for hard-to-treat cancers. Credit: Pawel Giovanni Cancemi/Shutterstock.com.
Debiopharm and SunRock Biopharma have signed an exclusive option and licence agreement to advance the development of specifically targeted antibody drug conjugates (ADCs) for hard-to-treat cancers.
Under the agreement, Debiopharm will further develop SunRock’s antibodies by incorporating its linker technologies, Multilink and AbYlink, for creating the new ADCs.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - DF-9001 in Gastric Cancer GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - PEG-irinotecan in Gastric Cancer GlobalData
View allCompanies IntelligenceMultilink, Inc.Debiopharm SASunRock Biopharma SLView all
SunRock Biopharma CEO Laureano Simón said: “We are really enthusiastic about the powerful synergy of SunRock antibodies and bispecific antibodies with Debiopharm’s ADC platform and clinical development capabilities.”
Multilink, a new cleavable linker platform intended for multidrug attachment, is compatible with any conjugation technology to create ADCs with a high drug-to-antibody ratio (DAR).
This technology enables multiple payloads loading on an antibody for improved therapeutic effect.
Pharmaceutical or other speciality biotech companies can use this platform for generating clinical-stage ADCs.
AbYlink is a rapid antibody conjugation technology for diagnostic uses and ADC preparation. It is a site-selective method that provides defined and invariable conjugation sites without any impact on antigen-binding regions.
Using this technology, researchers can design ADCs with improved safety, efficacy and specificity to meet the unmet medical requirements of patients through ADC innovation.
Debiopharm CEO Bertrand Ducrey said: “Our partnership with SunRock could result in the creation of highly innovative antibody-drug conjugates with the potential to tackle cancer in a new way and ultimately improve the lives of cancer patients.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.